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ABSTRACT Because of the similarities between the cystic fibrosis transmembrane conductance regulator (CFTR) and
multidrug resistance (MDR) proteins, recent observations of decreased plasma membrane electrical potential (At) in cells
overexpressing either MDR protein or the CFTR, and the effects of APV on passive diffusion of chemotherapeutic drugs, we
have analyzed chemotherapeutic drug resistance for NIH 3T3 cells overexpressing different levels of functional CFTR. Three
separate clones not previously exposed to chemotherapeutic drugs exhibit resistance to doxorubicin, vincristine, and
colchicine that is similar to MDR transfectants not previously exposed to chemotherapeutic drugs. Two other clones
expressing lower levels of CFTR are less resistant. As shown previously these clones exhibit decreased plasma membrane
At similar to MDR transfectants, but four of five exhibit mildly acidified intracellular pH in contrast to MDR transfectants,
which are in general alkaline. Thus the MDR protein and CFTR-mediated MDR phenotypes are distinctly different. Selection
of two separate CFTR clones on either doxorubicin or vincristine substantially increases the observed MDR and leads to
increased CFTR (but not measurable MDR or MRP) mRNA expression. CFTR overexpressors also exhibit a decreased rate
of 3H -vinblastine uptake. These data reveal a new and previously unrecognized consequence of CFTR expression, and are
consistent with the hypothesis that membrane depolarization is an important determinant of tumor cell MDR.
INTRODUCTION
Tumor cells selected on one chemotherapeutic drug (e.g.,
actinomycin D) may develop resistance to other chemother-
apeutics (e.g., anthracyclines, vinca alkaloids, epipodophyl-
lotoxins) concomitant with resistance to the selecting agent
(Biedler and Riehm, 1970). Multidrug resistance (MDR) is
associated with decreased intracellular retention of chemo-
therapeutic drugs that is due to some combination of re-
duced rates of drug influx (Beck et al., 1983; Sirotnak et al.,
1986; Ramu et al., 1989), altered intracellular binding (Beck
et al., 1983), and postulated active efflux of the drugs
(Dan0, 1973; Hammond et al., 1989). Documented overex-
pression of P-glycoprotein (p-gp or MDR protein) in these
cells and its relationship to resistance (Riordan and Ling,
1979) as well as the subsequent cloning of MDR genes
encoding this protein and elucidation of transporter gene
homology (Roninson et al., 1986; Scotto et al., 1986; Gros
et al., 1986), led to the proposal that MDR protein directly
catalyzes active drug efflux (Gerlach et al., 1986; Gros et
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al., 1986), and that this explains decreased cytoplasmic
retention of chemotherapeutic drugs.
Upon cloning of the gene defective in cystic fibrosis
patients (Riordan et al., 1989) it was immediately recog-
nized that the MDR protein and the cystic fibrosis trans-
membrane conductance regulator (CFTR) are homologous
members of an important family of transport proteins, the
"ABC" family (Higgins et al., 1990). CFTR functions as a
low conductance Cl- channel that is dependent on cyclic
adenosine monophosphate (Bear et al., 1992). The apparent
dramatically different function of the MDR protein and the
CFTR remains a curious and interesting topic of current
membrane transport research. Recent data (Valverde et al.,
1992; Gill et al., 1992; Altenberg et al., 1994; Bear, 1994;
Luckie et al., 1994; Hardy et al., 1995) suggest that MDR
protein may also be involved in modulating Cl- conduc-
tance, directly or indirectly. (Hypotonic swelling of some
cells overexpressing the MDR protein elicits increased
whole-cell Cl- conductance, or in some cases conductance
that is "hypersensitive" to the hypotonic challenge
(Valverde et al., 1992; Gill et al., 1992; Altenberg et al.,
1994; Luckie et al., 1994). Recent work (Hardy et al., 1995)
suggests protein kinase C may play an important role in
regulating the anomalous conductance. Thus, MDR protein
may either regulate endogenous Cl- conductance in some
cells, or perhaps transport Cl- directly. Other workers
(Ehring, 1994; Dong et al., 1994) have not observed in-
creases in Cl- conductance for cells overexpressing MDR
protein upon hypotonic challenge. Since all electrophysi-
ological study of Cl- conductance in MDR cells has been
with model systems grown for relatively long periods of
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time in the presence of potent chemotherapeutics, since
these selection procedures may induce altered expression/
regulation of additional ion transport proteins (Luz et al.,
1994), and since hypotonic shock is likely an indirect mech-
anism of "gating" the conductance mediated directly or
indirectly by the MDR protein, it is not surprising that some
variability has been noted. We believe more work with true
transfectants not previously exposed to chemotherapeutic
drugs (e.g., Valverde et al., 1992) may prove informative.)
A model for MDR protein activity that reconciles ion
transport function with drug transport function remains elu-
sive, although one suggestion is that ion transport anomalies
in MDR cells perturb plasma membrane electrical potential
and pHi and thus indirectly influence drug retention via
several different mechanisms (Roepe et al., 1993), and
another is that MDR protein "alternates" between CF- chan-
nel (or channel regulator) and drug pump conformations
(Gill et al., 1992).
The most direct support for the active drug pump model
for MDR protein is provided by recent drug uptake studies
with secretory vesicles isolated from Saccharomyces cer-
evisiae (Ruetz and Gros, 1994). Other studies have ques-
tioned the drug pump model (Roepe, 1992; Roepe et al.,
1993; Simon et al., 1994; Bornmann and Roepe, 1994; Luz
et al., 1994; Roepe, 1994), principally because of the fact
that MDR cells exhibit resistance to and/or decreased reten-
tion of a tremendous variety of compounds, including acti-
nomycin D, anthracyclines, colchicine, epipodophyllotox-
ins, ethidium bromide, gramicidin, mitomycin C, morphine,
nigericin, peptides, puromycin, reserpine, rhodamine, tech-
netium-sestamibi, topotecan, tetraphenylphosphonium,
Tween 20, valinomycin, verapamil, vinca alkaloids, and
yohimbine. An explanation for how one transport protein
could conceivably bind and actively transport this plethora
of agents is currently unavailable.
Since all compounds to which MDR cells are resistant
and/or exhibit decreased retention of are hydrophobic, and
since they are either weakly basic or cationic, or bind to
intracellular targets in a highly pH-dependent manner (or
are ionophores), an alternative possibility is that altered
compartmental or cytoplasmic pH and/or electrical mem-
brane potential promotes altered passive diffusion and par-
titioning of these compounds in such a way that availability
to "target" is decreased (Roepe et al., 1993), thus leading to
decreased retention and resistance. A unifying thesis that
attempts to explain both anomalous pHi and At regulation
in MDR cells is that altered Cl- translocation leads to
decreased plasma membrane electrical potential by increas-
ing CF- permeability and thus decreasing the dominance of
At by K+ conductance, and leads to altered pHi regulation
by disrupting normal ClF/FHCO3 exchange processes
(Roepe et al., 1993; Luz et al., 1994; Roepe et al., 1994).
Precisely how both perturbations are accomplished via
overexpression of one ion channel or channel regulator
remains to be determined.
An important prediction of this second model is that other
MDR. This would have extremely important implications
for understanding chemotherapeutic drug bioavailability at
the cellular level. Since it has recently been demonstrated
that overexpression of the CFTR leads to decreased At
(Stutts et al., 1993), presumably via increasing Cl- conduc-
tance, we tested whether 3T3 cells overexpressing consti-
tutively active CFTR exhibit an MDR phenotype. We have
also recently tested whether a CFTR-mediated MDR phe-
notype exhibits any similarities to the MDR protein-medi-
ated phenotype with regard to drug transport and retention
(L. J. Robinson and P. D. Roepe, submitted for publication).
MATERIALS AND METHODS
Materials
BCECF, di-4-ANEPPS, nigericin, and valinomycin were purchased from
Molecular Probes (Eugene, OR) and used without further purification.
Doxorubicin was obtained as a 2 mg/ml solution in saline (Adria Labora-
tories, Columbus, OH), colchicine in powder form was from Sigma Chem-
ical Co. (St. Louis, MO), and vincristine sulfate was obtained as a 1 mg/ml
solution in saline (Lilly, Indianapolis, IN). Vinblastine sulfate was a kind
gift of Lilly Research Laboratories. [3H]vinblastine sulfate (16 Ci/mmol)
and [3H]azidopine (52 Ci/mmol) were from Amersham International (Ar-
lington Heights, IL); purity of [3H]vinblastine was >95% as assayed by
high performance liquid chromatography with a Hypersil monolayer di-
methyloctysilyl column. The integrity of commercial 5% CO2 (balance air)
mixtures used in this work was checked using standard -HCO3 solutions
and application of the Henderson-Hasselbach relation. All other chemicals
were reagent grade or better, purchased from commercial sources, and used
without further purification or analysis.
Tissue culture
Construction of the cell lines used in this work has been described previ-
ously (Stutts et al., 1993). In brief, NIH 3T3 cells were seeded at 3 X 105
cells/30 cm2, transfected with a murine amphotropic retrovirus vector
harboring full length wild-type human CFTR cDNA and a neor marker, and
selected on 0.25 mg/ml active G418. CFTR was under control of the viral
long terminal repeat, and neor was under control of the simian virus 40
promoter. Surviving colonies were screened for CFTR overexpression by
Western blot (Stutts et al., 1993), and several clones (including C3, C5, and
C10 used in this work) were found to exhibit substantial Cl- conductance
and plasma membrane depolarization via electrophysiological methods
(see also Results). In some cases colonies were further selected on 100 nM
doxorubicin or 50 nM vincristine (see Results). A partial analysis of MDR,
MRP, CFTR, and anion exchanger protein and mRNA expression in these
lines is reported on here, and a more comprehensive analysis of these and
related cell lines will be reported elsewhere.
Cells were grown at 37°C in a 5% CO2 atmosphere in Dulbecco's
minimum essential medium (DMEM) supplemented with 100 U/ml peni-
cillin and 100 ,ug/ml streptomycin. Since we have documented that cell
lines transfected with the CFTR homologue MDR 1 may exhibit significant
alterations in the level of MDR protein expression even under continued
"selective pressure" with G418 or chemotherapeutics (Luz et al., 1994), we
have adopted the practice of discarding cell lines after six passages. Thus,
unless lines are recharacterized after six passages and evidence provided
that levels of expression of CFTR have not been altered, we consider the
line unsuitable for additional study.
For single-cell photometry analysis of pHi, cells were grown as above
on glass coverslips (Corning Glassworks, 18 mm2/0.11 mm thick) that
were immobilized in standard tissue culture plates with a dab of autoclaved
silicon vacuum grease (Dow-Corning). They were kept in media at 37°C
mechanisms that decrease At or alter pHi might lead to
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and 5% C02 Unt" immediately before mounting in a homebuilt perfusion
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chamber (Luz et al., 1994; Roepe et al., 1994). After mounting, cells were
immediately perfused with Hanks' balanced salt solution (HBSS) (118mM
NaCV/24.2 mM NaHCO3/1.3 mM CaCl2/O.5 mM MgCl2/0.6 mM
Na2HPO4/0.5 mM KH2PO4/10 mM glucose) that had been equilibrated
with 5% CO2 and to 37°C (see single-cell photometry, below).
Single-cell photometry and measurement of pH,
We have constructed a single-cell photometry apparatus by interfacing a
Nikon diaphot epifluorescence microscope and associated optics to a
Photon Technologies Inc. alphascan fluorometer (Luz et al., 1994; Roepe
et al., 1994; see Fig. 1). Signals from photon multiplier tubes connected in
T-format to the side port of the microscope were transferred to a Dell 433/L
computer and analyzed with PTI software (Photon Technologies Inc., New
Brunswick, NJ).
Cells were grown on sterile glass coverslips as described above and
used >1.5 but <4 days after plating, i.e., before confluency but after
several cell divisions. Coverslips were incubated with 5 ,uM BCECF-AM
for 30 min before mounting on the microscope stage, and they were then
continuously perfused at a constant rate (-6 mlmin) with HBSS buffer
equilibrated with 5% CO2 and to 37°C. Uniform BCECF staining was
verified visually and by monitoring the intensity of 490 nm excitation and
was found to be very similar for the different cells. Buffers harboring
-HCO3 were continuously purged with 5% C02, and a fine jet of 5% CO2
was directed over the mounted coverslip. Buffer pH was monitored with a
microelectrode. Several control experiments verified that leak of the es-
terifled BCECF-AM was minimal in the time required to make a measure-
ment, and not any different for CFTR versus control transfectants. BCECF
calibration curves obtained as described (Luz et al., 1994) for these cell
lines verify pHi-dependent behavior of BCECF is nearly identical for the
different cell lines. Exposure to excitation light was limited to the time of
data collection to limit photobleaching.
To calculate steady state pHi, excitation ratios were collected for 20-25
individual cells perfused with HBSS as described. Then, using the same
coverslip, calibration curves were obtained using the K+/nigericin titration
approach of Thomas et al. (1979) as described previously (Roepe, 1992;
Roepe et al., 1993), but in a "single-cell mode" wherein buffer harboring
nigericin was continuously flowed over the cells (Luz et al., 1994). Cali-
bration curves harbored six points between 6.60 and 8.00 (±0.03 pH units;
each point was the average of 12-15 cells (see Luz et al., 1994), and were
well fit by an exponential (R2 > 0.95). pHi was calculated in this way for
each cell line three to four times, using three to four separate coverslips,
and the data averaged.
Cell survivability
We assayed drug resistance by colony formation assays. Cells were har-
vested by trypsinization and resuspended in DMEM pre-equilibrated to
37°C and 5% CO2. They were plated at 500 cells/well using standard
six-well plates. Chemotherapeutic drug was added, and cells were allowed
to grow for 7 days. The plate was then stained with methylene blue, and the
colonies scored visually. For each assay, survivability at a given drug
concentration was determined in duplicate and the data averaged. Data
shown in Results are the averages of three separate assays performed on
different days.
We also checked resistance by growth inhibition assays. Cells were
subcultured in 96-well plates and incubated overnight at 5% CO2. Drug at
various concentrations was added the following day and cells were grown
for 3 days more at 5% CO2. Cell growth was assayed by SRB staining as
described (Skehan et al., 1990). We verified that staining was a linear
function of both cell number and total cell-associated protein for these cell
lines grown under the different conditions.
Northem blotting
RNA was isolated by the method of Chomczynski and Sacchi (1987), and
Northern blots were performed under high stringency as described (Roepe
et al., 1993). 0.7 kb NdeI/HindlII, 1.1 kb EcoRI and 0.8 kb Pstl fragments
from human MDR 1 cDNA, human ,3-actin cDNA, and acidic ribosomal
phosphoprotein (rPO) cDNA, respectively (kindly provided by Drs. P.
Borst and K. Scotto), were used to probe for human MDR 1, ,3-actin, and
rPO. MRP cDNA was kindly provided by Dr. S. Cole (Cole et al., 1992).
Probes were labeled by the random priming method. Blots were visualized
by autoradiography (exposure times varied from 4-6 h for ,B-actin and rPO
and up to 72 h for MDR and MRP; we used Kodak X-OMAT film)
Single Cell Photometry Assembly
FIGURE 1 Schematic of the single-
cell photometry apparatus used to mea-
sure intracellular pH (pH;). A fiber op-
tic was used to direct excitation to the
epifluorescence microscope and a 510
nm dichroic reflected 439/490 nm light
but passed intracellularly trapped
BCECF emission centered at 535 nm.
See Materials and Methods and Luz et
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(Eastman Kodak, Rochester, NY), and levels of mRNA were quantitated
by imaging a-radiation with a Betascope 603 blot analyzer (Betagen), or by
autoradiography followed by densitometry using a Stratagene stratascan
7000 interfaced to an AST personal computer. The intensities of bands of
interest were normalized relative to background emission from the blot,
and CFTR expression was ratioed versus that for 13-actin.
Reverse transcriptase polymerase chain reaction
(RT-PCR)
In an attempt to detect trace MDR and MRP mRNA in various cell lines,
and to construct a convenient 550 bp cDNA probe for CFTR mRNA, we
used RT-PCR essentially as described (Bremer et al., 1992; Noonan et al.,
1990) with several modifications. A master mix containing magnesium,
diethylpyrocarbonate-treated deionized water, deoxynucleotides, RNase
inhibitor, and reverse transcriptase was prepared and then 20 Pl aliquoted
into individual reaction tubes. Alternatively, if a large-scale reaction was
carried out, the reagents were added individually to the tubes in the order
listed above. The large-scale reaction had a total volume of 80 plI. Appro-
priate primers (typically 10 pmol each) and template (typically 1 ,ug total
RNA) were then added to the tubes. The final concentrations of reagents
were 5 mM MgCl2, 1 X Perkin-Elmer PCR Buffer II (50 mM KCl, 10 mM
Tris-HCl, pH 8.3; Perkin-Elmer Cetus, Norwalk, CT), 1 mM dATP, 1 mM
dCTP, 1 mM dGTP, 1 mM dTTP, 1 U/,ul RNase inhibitor, 2.5 U/,lp murine
leukemia virus reverse transcriptase, 2.5 ,uM random hexamer primers(Perkin-Elmer Cetus), and 0.88-4.17 ,g RNA.
The reaction mixture was incubated at room temperature for 20-40
min, and then the tubes were placed in a Perkin-Elmer Gene Amp PCR
System 9600 and cycled once through the following program: reverse
transcription (15 min at 42°C), denaturation (5 min at 99°C), cooling (5
min at 5°C). The resultant cDNA template was amplified by PCR: ,-mi-
croglobulin primers were included with the target primers, and reactions
with the two sets of primers were also carried out in separate tubes and the
data compared. The tubes were cycled as follows: hold (5' at 95°C) 40
cycles (30 s at 95°C/30 s at 55°C/75 s at 72°C); hold 10 min at 72°C.
Standard quantitation curves were also generated with known amounts of
RNA and plasmid DNA.
The PCR fragments were electrophoresed on 0.8% agarose and stained
with ethidium bromide. Gels under ultraviolet (UV) illumination were
photographed with a Polaroid camera. The photographs were scanned with
a LaCie scanner interfaced to a Macintosh Quadra computer, and analyzed
with photoshop software. The method works very well for low levels of
anion exchanger, MDR, MRP, and CFTR expression, and will be described
in more detail elsewhere (M. M. Hoffman and P. D. Roepe, manuscript in
preparation). We very easily detect CFTR mRNA in the C3, CS, and C10
clones (not shown, see below) but not MDR mRNA, even though we can
very easily detect it in other cell lines known to express the message(M. M. Hoffman, L. Y. Wei, and P. D. Roepe, unpublished data).
A 550 bp RT-PCR product was isolated in high yield from the CFTR-
expressing C10 clone (see Results). This fragment corresponds to the 5'
region of the published cDNA sequence (Riordan et al., 1989) and is
defined by the primers 5' CCC GAG AGC TCA ACA TGC AGA GGT
CGC CT 3' and 5'TAC ITA T1T TAT CTA GAA CAC GGC 3'. After
PCR, the fragment was analyzed by restriction analysis using either AluIor
NciI. Predicted patterns based on the published cDNA sequence (Riordan
et al., 1989) were verified by agarose gel electrophoresis. This probe was
also random-primed and used in Northernblot analysis as described above.
Western blotting
Western blotting was performed as described (Luz et al., 1994; Wei and
Roepe, 1994) using the monoclonal antibody C219 and the ECL detection
Drug uptake
Uptake of 3H-vinblastine was as described (Wei and Roepe, 1994). Briefly,
cells were subcultured in six-well plates at 5 X 105 cells/well and then
incubated overnight at 5% CO2 before performing the assay. Each well was
incubated with 0.5 ,uM [3H]vinblastine (200 mCi/mM) at 5% CO2 for
variable time. The wells were then washed with cold media to remove
uninternalized vinblastine. Radioactivity in the cells, incubation media, and
wash media was assayed by liquid scintillation spectrometry. Total cell-
associated protein was quantitated by an amido black assay. We verified
that the average protein content per cell was similar for the different cells.
Zero uptake was determined by incubation in buffer at 4°C.
Measurement of cell volume
Total cell volume was calculated after determining the mean particle size of
cell suspensions by the single threshold Coulter method (Kachel, 1990) per-
formed with a ZM Coulter counter (Coulter Scientific Instruments, Hialeah,
FL), as described in detail previously (Roepe et al., 1993), using polystyrene
beads of various sizes to calibrate. We have previously determined that
size/voltage calibration curves obtained by this method allow for extremely
reproducible (±0.5 ,m) mean particle size determination from suspensions of
3-4 X 104 cells, using three plots of counts versus voltage (see Roepe et al.,
1993; Kachel, 1990), with each count performed in triplicate.
For some cell lines, we also measured intracellular water volume by
ratioing '4C-inulin versus 3H20 disintegrations per minute (dpm) as described
(Rottenberg, 1979). 1 X 106 cells in 1 ml of HBSS/10 mM HEPES, pH 7.3,
were incubated with 1 ,uCi of 3H20 water and 15 ,uCi of '4C-inulin at 37°C,
and the cells were then isolated by centrifugation. Radioactivity in the super-
natant and the cell pellet was quantitated with a dual channel 14C/3H dpm
program using a Beckman LS 5801 scintillation counter. 14C and 3H quench
curves were calculated using known dpm in the same buffer and scintillation
fluid volumes that were used in individual experiments (see also Roepe et al.,
1993).
Photolabeling with [3Hjazidopine
We followed the protocol of Bruggemann et al. (1989) with some modi-
fications. According to the General Electric Co. (Wendell Phelps, personal
communication), the UV lamp used in Bruggemann et al. (1989) emits
light centered at -365 nm. In brief, 1 X 106 cells were harvested, washed
with phosphate-buffered saline (PBS), resuspended in 100 ,ul PBS, and
placed in wells of a 96-well polystyrene plate. They were incubated with
1 ,uCi of 3H-azidopine (52 ,uCi/nmol) for 60 min at room temperature in
the dark, and then photolabeled under a UV lamp (General Electric,
3020-BLB) at 4°C. This lamp emits light centered at 366 nm (bandwidth
-80 nm). Applied and emitted power values are 8.0 and 0.8 W, respec-
tively. The distance between the lamp and the samples was varied in
different experiments (as was the time of illumination; see Results) but was
typically '2.5 cm. Labeling was also performed with a higher energy lamp
(UVP, San Gabriel, CA) with emission centered at 255 nm. Labeled cells
were collected and lysed in cracking buffer (50 mM Tris, pH 6.8/10%
glycerol/10mM DT`T/2% SDS/0.1% bromophenol blue) and resolved by
SDS/PAGE as described (Wei and Roepe, 1994). Gels were dried and
autoradiography was carried out at -80°C. In some experiments, before
drying, gels were soaked in Autofluor (National Diagnostics) essentially
according to the manufacturer's instructions (several incubation times were
shortened because we used thin gels), to increase the efficiency of 3H
detection.
RESULTS
MDR phenotype for CFTR clones not previously
exposed to chemotherapeutics
Chemotherapeutic drug resistance was measured by colony
method (Amersham International).
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formation in growth media harboring a range of chemother-
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apeutic drug concentrations (Fig. 2). Several recently de-
scribed clones isolated after transfecting NIH3T3 cells with
CFTR cDNA (Stutts et al., 1993) showed resistance to
several chemotherapeutics that was significantly greater
than the control (Table 1). Notably, these clones were not
previously exposed to chemotherapeutic drugs. Analo-
gously, cells transfected with human MDR 1 (M. M. Hoff-
man and P. D. Roepe, submitted for publication) or MRP
cDNA (Grant et al., 1994) that are not previously exposed to
chemotherapeutic drugs before the drug resistance assay
typically exhibit 2- to 10-fold levels of drug resistance, and
non-drug-selected murine (mu) MDR 1 transfectants (Gros
et al., 1991; Devault and Gros, 1990) have been reported to
exhibit between 3- and 20-fold levels.
(The vast majority of cell lines used to study MDR protein
function have been selected for long periods of time with
potent chemotherapeutic drugs. Some protocols for creating
MDR "transfectants" also include growth on chemotherapeutic
drugs. It is important to recall that levels of drug resistance due
solely to MDR protein overexpression (without any possible
complications due to additional effects caused by chemother-
apeutic drug selection) have only been examined in a few
studies. Guild et al. (1988) infected NIH3T3 cells with mu
MDR cDNA via retroviral-mediated transfer and screened 12
colonies for drug resistance. These clones were not selected
with chemotherapeutic drug before analysis and were found to
be '-2.7-fold resistant to doxorubicin (mean 1.3-fold), vinblas-
tine (mean 1.7-fold), and colchicine (mean 1.4-fold). Mass
populations of true mu MDR 1/LR73 transfectants (Devault
and Gros, 1990) exhibit similar resistance, whereas several
well-expressing clones from this study were found to be more
resistant (3- to 20-fold, depending on the drug and MDR
protein isoform). Increased resistance for some of these mu
MDR clones might be due in part to recently observed elevated
pHi (Luz et al., 1994), which is predicted to increase MDR










levels of resistance for two true MRP clones (T-2 and T-5)
not previously exposed to chemotherapeutics (Grant et al.,
1994) are also similar to the levels seen for these CFTR
transfectants.)
These CFTR clones were previously shown to exhibit
significant CF- conductance and plasma membrane depo-
larization, as measured by voltage clamping (Stutts et al.,
1993; see Table 1). This is due to overexpression (con-
firmed by Western blot; see Stutts et al., 1993) of the CFTR,
which functions as a low conductance Cl- channel (Bear et
al., 1992). Thus, decreased AT and increased Cl- conduc-
tance verifies the expression of functional CFTR in these
cells.
As the CFTR clones are grown in increasing concentra-
tions of either doxorubicin, vincristine, or colchicine (Fig.
2), there is a marked increase in the number of surviving
colonies of >50 cells, relative to control cells also selected
on G418 (Stutts et al., 1993). Similarly, growth inhibition
assays as performed for low-level MDR kidney carcinoma
cells (not shown; see Wei and Roepe, 1994) reveal measur-
able resistance to doxorubicin, vincristine, and colchicine
for the CFTR transfectants, but they are not resistant to
methotrexate (not shown). This pattern of chemotherapeutic
drug resistance is very similar to that exhibited by other
cells that become MDR via overexpression of the MDR
protein. However, interestingly, resistance does not appear
to be related to relative alkalinization of the cytosol as seen
for cells overexpressing MDR protein (Keizer and Joenje,
1989; Thiebaut et al., 1990; Roepe et al., 1993; Luz et al.,
1994), since these CFTR transfectants do not exhibit ele-
vated pHi (Table 1). In fact, four of five clones exhibit
mildly acidic pHi, relative to the control transfectants. Per-
haps of interest is the previous observation (see Stutts et al.,
1993) that C5, the one clone that does not exhibit lower pHi,
is also the one CFTR clone that is apparently unresponsive
to forskolin. We do not note significant alterations in total
10 100 1 10 100
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FIGURE 2 Resistance to (A) doxorubicin, (B) vincristine, (C) colchicine as measured by colony formation assays for several CFTR-overexpressing
colonies (C3, 0; C5, *; and CIO, 0') and control 3T3 transfectants (O) created as described (Stutts et al., 1993). Note there is 85% survivability for the
control transfectants at 4 ,uM doxorubicin (not shown, but see Fig. 5 A). All cells were maintained at 37°C and 5% CO2 in DMEM supplemented with 10%
fetal calf serum and 200 U/1 each of penicillin and streptomycin and 0.25 mg/ml G418. Cells were harvested by trypsinization, and 500 cells were plated
per well of a six-well plate and allowed to attach for several hours in the absence of G418. Cells were then grown at 37°C and 5% CO2 in DMEM harboring
increasing concentrations of the chemotherapeutics. After 7 days, the plates were stained with methylene blue, and the number of colonies was scored
visually. The number of colonies in the wells harboring no chemotherapeutic drug was similar for all the cell lines, and averaged between 85 and 110
colonies/well. For each assay, % plating efficiency at a given drug concentration (relative to the cell line grown in the absence of drug) was analyzed in
duplicate. Data shown are the average of three separate assays (SE < 5%). Each data set was fit by a function of the form y = (a)10(-b)x, using five data
points (including no drug); R2 was > 0.95 in each case. Fold resistance (Table 1) was computed using the IC50 values calculated from these fits.
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TABLE 1
AT Mean cell Fold resistance to
Voltage diameter
Cell line clamp ANEPPS pH; (AM) Doxorubicin Vincristine Colchicine
3T3/cont 58 61 7.37 ± 0.05 15.3 1.0 1.0 1.0
C3 35 27 7.21 ± 0.04 15.8 4.2 4.1 3.5
C5 34 43 7.43 ± 0.05 16.1 3.2 6.0 4.5
C1o 27 23 7.15 ± 0.04 15.5 4.2 2.8 2.3
C1l 45 50 7.06 ± 0.04 14.7 1.4 1.3 1.1
C12 47 53 7.11 ± 0.04 16.3 1.3 1.5 1.2
Electrical membrane potential (At), intracellular pH (pHi), size, and fold chemotherapeutic drug resistance for control 3T3 transfectants and five clones
expressing different levels of CFTR (Stutts et al., 1993). Values for AV determined by voltage clamp (±4 mV) are taken from Stutts et al. (1993). AT
was also determined by the K+/valinomycin null point titration method using di-4-ANEPPS as described (Roepe et al., 1993; Luz et al., 1994) in a
double-blind fashion; values shown are the averages of three determinations (SE < 7.5%). pHi was measured by single-cell photometry using BCECF as
described (see Materials and Methods and Luz et al., 1994). Note that mild acidification of pHi for one CFTR transfectant has also been noted in a previous
study (Elgavish, 1991). Calibration of BCECF response was by the K+/nigericin method at six different pH (see Materials and Methods); curves were well
fit by an exponential (R2 > 0.95 in each case) and there was no significant difference in BCECF responses for the different cells. Fold resistance to the
chemotherapeutics was by ratioing calculated IC50 values from the curves presented in Fig. 2. Variability among different clones of control transfectants
was < 1.2-fold. In additional work vinblastine resistance for C3 was found to be 3.7-fold. Cell diameter was calculated via the Coulter method (see Materials
and Methods); values shown are the average of three determinations based on three size versus voltage plots (variability ' 0.6 ,um).
cell volume (mean cell size or average water volume, see
Table 1) for the CFTR transfectants.
Importantly, the drug resistance exhibited by the CFTR
transfectants is not due to expression of MDR protein or
mRNA. In fact, similar to others (Currier et al., 1992) we
cannot demonstrate expression of any significant MDR
protein or mRNA for the parental 3T3 cells or the CFTR
expressers via our sensitive Western and Northern proce-
dures (Luz et al., 1994; Wei and Roepe, 1994), which we
have previously demonstrated are capable of detecting very
low levels of endogenous expression. We are also unable to
measure increased MDR or MRP mRNA via overexposure
of Northern blots or by RT-PCR (not shown; see Materials
and Methods). In any case, based on previous analysis of
low-level MDR cells (Luz et al., 1994; Wei and Roepe,
1994) or low-level MRP-expressing MDR cells (Grant et
al., 1994), we can firmly conclude that any trace MDR
protein or MRP expression that may avoid detection would
not be sufficient to confer the measured drug resistance.
These data indicate the measured MDR is not due to MDR
protein or MRP overexpression.
In contrast to previous analysis of MDR cells created by
selection with chemotherapeutic drugs, the calcium channel
blocker verapamil does not appear to reverse the drug
resistance exhibited by these cells in growth inhibition
assays, at levels of verapamil that are not cytotoxic (data not
shown). However, we are unaware of any studies that have
shown verapamil reverses low-level MDR in MDR-protein
overexpressing cells not previously exposed to chemother-
apeutic drugs.
Photolabeling with [3H]azidopine
Another yardstick of the MDR phenotype used by many
laboratories is photolabeling of the MDR protein with var-
ious azido compounds, including [3H]azidopine (Green-
berger et al., 1990). In repeated attempts using various UV
sources, concentrations of cells or azidopine, time of illu-
mination (up to 90 min), and distance between illumination
and sample (see Materials and Methods), we were unable to
demonstrate efficient photolabeling of the CFTR protein
above background (Fig. 3) even though we were able to
efficiently photolabel mu MDR 1 protein in 1-1 cells (Fig.
3, lane 6), which express a very high level of the protein
(Gros et al., 1991; Luz et al., 1994). However, we stress that
the levels of CFTR protein in these transfectants are low,
and no one to our knowledge has ever demonstrated effi-
cient photolabeling of low levels of MDR protein above
considerable background using MDR transfectants not pre-
viously exposed to chemotherapeutic drug. As shown in
Fig. 3 we too are unable to demonstrate efficient photola-
beling of mu MDR 1 protein in EX4N7 cells ("true" trans-
fectants not previously exposed to chemotherapeutics; see
Devault and Gros, 1990). This is also the case for a variety
of other photoaffinity probes under a variety of conditions
(Dr. L. M. Greenberger, personal communication). Thus,
these negative data for CFTR do not necessarily indicate
that photolabeling of high levels of CFTR with [3H]azido-
pine (in analogy to previous work with MDR protein) is
impossible.
Altered drug transport for CFTR clones
The MDR phenotype is associated with decreased intracel-
lular retention of chemotherapeutic drugs, that is due to
some combination of reduced rates of influx (Beck et al.,
1983; Sirotnak et al., 1986; Ramu et al., 1989), altered
intracellular binding (Beck et al., 1983; Roepe, 1992),
and/or postulated active efflux (Gros et al., 1986; Gottes-
man and Pastan, 1988; Higgins and Gottesman, 1992).
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FIGURE 3 Photolabeling with [3H]azidopine. 1 X 106 cells were pre-
pared as described in Materials and Methods and photolabeled for 60 min.
After SDS/PAGE the gel was soaked in autofluor, dried, and exposed for
48 h using Kodak X-OMAT film. (Lane 1) 3T3 control transfectants; (lane
2) C3; (lane 3) CS; (lane 4) LR73 CHO cells (parent for cells in lanes 5 and
6); (lane 5) EX4N7 cells (a "true" mu MDR 1 transfectant; see Devault and
Gros, 1990); (lane 6) 1-1 cells, which are essentially the cells in lane 5
further selected on 50 ng/ml vinblastine for several months. 1-1 cells
express at least 10-fold more MDR protein relative to EX4N7 (see Luz et
al., 1994). The only band efficiently labeled is mu MDR 1 protein in the
highly overexpressing 1-1 cell line. Note that further exposure, higher
energy illumination, the use of 3 X 106 cells, or up to 5 ,Ci [3H]azidopine
per reaction does not reveal efficient photolabeling of the mu MDR 1
protein in EX4N7 or the CFTR protein in C3 or CS (not shown). Upon
further exposure, many dozens of additional bands are revealed (not
shown), and it is thus impossible to distinguish any photolabeling of lower
levels of the ABC transporters above background. We would thus argue
that the photolabeling of MDR protein is not as specific as sometimes
interpreted, but we stress that many other investigators argue differently.
Thus, in Fig. 4 we compare accumulation of 3H-vinblastine
for C3 and the control cells. Clearly, overexpression of
functional CFTR lowers the rate of drug accumulation.
Similar decreased rates of accumulation have been seen for
MDR transfectants (Hammond et al., 1989) although in this
study the MDR transfectants were selected on chemothera-
peutic drug before drug transport, so the data are not directly
comparable. In any case, uptake for C3 approaches equilib-
rium in 60-70 min, and intracellular levels are lower for C3
at 60 min. Conversely, we find no evidence for increased
rates of drug efflux for the CFTR transfectants (L. J. Rob-
inson and P. D. Roepe, submitted for publication). Similar
reduced rates of accumulation for doxorubicin as measured
with fluorometric methods (Ramu et al., 1989; Roepe, 1992;
Bornmann and Roepe, 1994) are also observed for C3 and
other CFIR clones (L. J. Robinson and P. D. Roepe, sub-
mitted for publication).
Phenotype of CFTR transfectants after low-level
doxorubicin selection
With a few exceptions (e.g., Guild et al., 1988; Devault and
Gros, 1990), resistance for MDR transfectants has always
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FIGURE 4 Accumulation of [3H]vinblastine in control transfectants (El)
and the C3 CFTR transfectant (*). Cells were grown as described in
Materials and Methods and exposed to 0.5 ,XM 3H-vinblastine (200 plCi/
,uM), and the supernatant and cell pellets were collected at various times
(Wei and Roepe, 1994). Accumulation at zero time was measured by
incubating the cells with 3H-vinblastine in media preequilibrated to 4°C (a
non-permissive temperature for influx). In each assay, each time point was
performed in duplicate and the data averaged. Curves shown are the
average of three assays performed on three different days; SE < 10%.
motherapeutic drug. Quantitative comparison of the MDR
exhibited by these CFITR clones and the majority of MDR
transfectants that have been created is thus difficult due to
different levels of CFTR versus MDR protein expression
and other complications caused by the chemotherapeutic
drug selection (including likely induction of additional,
non-MDR protein-mediated resistance mechanisms in the
drug-selected transfectants). Levels of resistance for true
MDR or MRP transfectants (non-chemotherapeutic drug-
selected) are comparable to those that we measure here (Fig.
2) for the CFTR transfectants (Guild et al., 1988; Devault
and Gros, 1990; M. M. Hoffman, L. Y. Wei, and P. D.
Roepe, unpublished; see earlier parenthetical note in the
section "MDR phenotype for CFTR clones not previously
exposed to chemotherapeutics").
As is the case for true mu MDR transfectants (Devault
and Gros, 1990), after these CFTR clones are selected on
either 100 nM doxorubicin or 50 nM vinblastine for 10-14
days, resistance to doxorubicin, vincristine, and colchicine
is raised substantially (Fig. 5). This selection leads to severe
growth arrest for the control transfectants and essentially
complete cell death within an additional 7-10 days of se-
lection, but allows for facile isolation of rapidly expanding
resistant colonies for the CFTR overexpressers. The in-
creased resistance is not due to increased MRP or MDR
protein expression as measured by RT-PCR or Northern
blot (see above). In fact, short-term, low-level selection with
doxorubicin or vincristine appears to elevate CFTlR mRNA
levels several-fold for mass populations of C3 or C5 cells
(see Fig. 6 A).
We further tested this result by selecting a single CFTR-
expressing clone with 100 nM doxorubicin as above, and
then expanding seven randomly picked individual drug-
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FIGURE 5 Resistance to (A) doxorubicin (dox), (B) vincristine (vcr), and (C) colchicine (col) as measured by colony formation assays for control 3T3
transfectants (L) and colony C3 selected for 2 weeks on 100 nM doxorubicin (C3D1; *). Fold resistance for C3D1 is -8.9, 7.7, and 10.5 to doxorubicin,
vincristine, and colchicine, respectively. Similar increased MDR is seen for other CFTR colonies selected for short periods of time on either 100 nM
doxorubicin or 50 nM vincristine. Similar selection for the control transfectants yields no surviving cells. More detailed comparison between different drug
selected colonies will be published elsewhere. For each assay, drug concentrations were analyzed in duplicate. Data shown are the average of two separate
assays. Each data set was fit by a function of the form y = (a)10(-b)x; R2 was > 0.91 in each case.
resistant colonies for 3 weeks in the presence of doxorubi-
cin. RNA was isolated, and Northern blot analysis (Fig. 6 B)
revealed increased CFTR mRNA in all of the clones; no
clones exhibiting similar (or lower) CFTR expression were
found. Overexpression varied between 2.2- and 4.8-fold
(mean 2.9-fold) among the different clones. This degree of
variable CFTR expression is not seen in subclones of the
original CFTR clones grown in the absence of doxorubicin.
The results indicate that low-level, short-term selection with
chemotherapeutics may elevate CFTR mRNA in some cells.
Relationships between resistance, CFTR
expression, and At or Ali
The data described above point to interesting similarities
between the CFTR and MDR protein-mediated MDR phe-
notypes. As a first attempt to analyze these, in Fig. 7 we plot
the relationships between drug resistance and relative
[CFTR] as determined previously (Fig. 7 A; Stutts et al.,
1993); At for the five clones computed as the average
between the voltage clamp and di-4-ANEPPS determina-
tions (Fig. 7 B); and computed A-H, where the chemical
gradient in H+ (in mV) is added to ,I for the different cells
(following the convention that alkaline inside ApH is neg-
ative) (Fig. 7 C). We are unaware of any similar plots for
MDR cells that are MDR solely by virtue of overexpression
of MDR protein or MRP.
With the exception of particularly high antimitotic resis-
tance for C5, there is in general a positive relationship
between drug resistance and relative CFTR expression (Fig.
7 A). The relationship is smoothest for doxorubicin. We
note that C5 is the sole CFTR clone previously character-
ized (Stutts et al., 1993) as unresponsive to forskolin stim-
ulation. When resistance is plotted relative to the At (Fig.
7 B), an apparent decline in resistance to the antimitotics is
seen at low AP, again because of the behavior of C5 and
also the C10 clone, which is the most acidic of the signif-
icantly depolarized clones (Table 1). A strong positive re-
lationship is again seen for doxorubicin, which apparently
begins to plateau near -30 mV.
When the pH gradient is taken into consideration and
resistance plotted versus computed electrochemical poten-
tial (Fig. 7 C), the data points cluster much nearer each other
and the divergence in the trends for the antimitotics seen in
Fig. 7 B becomes less pronounced. These data, along with
previous work (Luz et al., 1994; Roepe et al., 1993) empir-
ically suggest that there is a possible additive effect of
decreased At and alkaline pHi with regard to resistance,
whereas acid pHi and decreased At may be antagonistic,
particularly with regard to resistance to the antimitotics.
This could be due to a different pH dependency for anti-
mitotic binding to tubulin in this pHi range relative to
anthracycline binding to nucleic acid (see Mukhopadhyay et
al., 1990).
Without similar plots for true MDR transfectants, it is
difficult to compare these trends to those that likely exist for
true MDR transfectants. However, for drug-selected MDR
cells that overexpress MDR protein, in general, a positive
relationship is observed when relative [MDR protein] is
plotted versus resistance. This relationship typically pla-
teaus early in the second log of resistance. This also appears
to be the case when decreased At or increased ApH is
plotted versus resistance (see Roepe et al., 1993). The At
versus doxorubicin resistance plot for a series of drug se-
lected MDR myeloma cells analyzed previously (Roepe et
al., 1993) appears to plateau near 50% membrane depolar-
ization, as also appears to be the case for the series of CFTR
transfectants. Thus, although the CFTR and MDR protein
mediated MDR phenotypes are different (notably with re-
gard to pH1); they appear to share some important features.
DISCUSSION
Including the data in this paper, overexpression of three
different eukaryotic ABC transporters has been associated
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Grant et al., 1994). Three theories invoked to explain MDR
currently receive attention; thus we shall address the present
8 data in the context of these models.
The first theory postulates that the MDR protein is a
multisubstrate pump (Gros et al., 1986; Gerlach et al., 1986;
Gottesman and Pastan, 1988; Ruetz and Gros, 1994) that is
somehow able to bind and actively efflux a large variety of
structurally divergent compounds including actinomycin D,
<0 anthracyclines, colchicine, cyclosporin A, morphine, vali-
nomycin, various peptides, vinca alkaloids, and many oth-
ers; i.e., MDR protein directly transports drugs. This model
has recently been extended to suggest that the protein prod-
uct of the MRP gene is also a multisubstrate drug pump
(Zaman et al., 1994); however, more detailed thermody-
namic and kinetic data (showing transport by MRP against
a substrate concentration gradient at a rate faster than pas-
sive diffusion) are required to unequivocally support MRP
drug pumping activity.
The pump model is widely accepted among researchers
that study chemotherapeutic drug resistance, but remains
controversial because of the difficulty in rationalizing the
lack of specificity. Recent data have been obtained in sup-
port of this model for MDR protein (Ruetz and Gros, 1994;
Sharom et al., 1993; Shapiro and Ling, 1995); however,
estimated turnover from these studies (drug molecules
translocated/MDR protein molecule/min) reveal a measured
process that is extremely slow and 103-105-fold slower than
is estimated to be required to explain altered drug accumu-
lation and retention in MDR cells (Demant et al., 1990; see
also Simon and Schindler, 1994; Bornmann and Roepe,
1994; Roepe, 1994, 1995). In addition, several recent ki-
netic studies of drug efflux are inconsistent with the active
drug efflux model (Roepe, 1992; Bornmann and Roepe,
kb 1994; L. J. Robinson and P. D. Roepe, submitted for pub-lication). For these reasons and others we do not favor this
interpretation for the CFTR-mediated MDR phenotype.
9.5 The second model (Roepe et al., 1993, 1994; Luz et al.,
7.5 1994) theorizes that MDR protein overexpression alters
4.4 FIGURE 6 Northern blot analysis of relative CFTR expression for trans-
fectants selected on low levels (100 nM) of doxorubicin for short periods
of time (see Materials and Methods). In (A), RNA was isolated from mass
2 4 populations of either C3 (left) or CS (right) after selection, and probed with
a 550 bp CFTR fragment (see Materials and Methods). Lanes 1 and 5 are
3T3/c control transfectants, lanes 2 and 6 are C3 and C5 before drug
1.4 selection, lanes 3 and 7 are C3 and C5 selected on doxorubicin in the
presence of G418, and lanes 4 and 8 are C3 and C5 selected on doxorubicin
in the absence of G418. Fold overexpression varied between 2.1 and 3.5 in
the different examples (see Materials and Methods); control j3-actin hy-
bridization is shown at the bottom. Similar data were obtained via selection
with 50 nM vincristine (not shown). In (B), a single CFTR clone (lane 2)
was similarly selected with doxorubicin, and seven individual resistant
colonies that appeared within 10 days (lanes 3-8) were picked and prop-
agated in 100 nM doxorubicin for an additional 2 weeks. Lane 1 is a control
3T3/c transfectant that does not express CFTR. CFTR overexpression in
the drug selected clones varied between 2.2- and 4.8-fold (see Materials
and Methods). Note that our CFTR probe is highly specific in these high
stringency Northerns (see Materials and Methods) and that MDR and MRP
mRNA are about 2.6 and 1.8 kB smaller than this CFTR mRNA, respec-
tively. The blot is slightly overexposed to enhance the signal in lane 2.
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FIGURE 7 Plot of resistance to the different chemotherapeutics versus
(A) relative expression of CFTR in the series; (B) relative At; and (C)
computed plasma membrane A-H i.e., the sum of At and the computed
chemical gradient in protons. (El) Doxorubicin resistance; (*) vincristine
resistance; and (i) colchicine resistance. See text for discussion.
plasma membrane electrical potential (At) and/or pHi (i.e.,
MDR protein overexpression alters the character and/or
magnitude of plasma membrane electrochemical potential),
which then affects passive diffusion and target binding
efficiency and hence alters retention/partitioning of the
drugs via several different mechanisms; i.e., MDR protein
indirectly promotes decreased intracellular drug accumula-
tion. This model can be extended to account for altered
compartmentalization of drugs seen in resistant cells that do
not express MDR protein (i.e., other mechanisms that per-
turb potential for plasma membrane or other compartmental
membranes may contribute to drug resistance, such as over-
expression of vacuolar H+ ATPase; see Ma and Center,
1992) and also ties together a variety of other curious
observations for MDR cells that currently elude interpreta-
tion via the first model, such as dramatic overexpression of
Na+/H+ and C1-/-HCO3 exchanger mRNA in MDR cells
(Roepe et al., 1993; Luz et al., 1994) and the provocative
resistance that MDR cells exhibit to a variety of ionophores.
It may also provide a satisfying explanation for why differ-
ent cells expressing similar levels of MDR protein exhibit
different levels of resistance, since maintenance of plasma
membrane potential is different in various eukaryotic cell
types. Importantly, it is currently not known whether ele-
vated pHi and decreased At are additive or synergistic with
regard to chemotherapeutic drug resistance, or relatedly
whether lower pHi and decreased At are antagonistic (see
Table 1), which may be particularly important to under-
standing the differences between the MDR protein and
CFTR-mediated MDR phenotypes as well as patterns of
gene expression in CFTR overexpressers selected for higher
levels of drug resistance (L. Y. Wei and P. D. Roepe,
manuscript in preparation). Along with the large volume of
data pertaining to CFTR channel function, which is pre-
dicted by theory and verified by experiment (Stutts et al.,
1993) to lead to altered plasma membrane potential when
the channel is overexpressed, this model presents a logical
framework for interpreting the data in this paper.
A third model, through identification of anomalous CF-
conductance in MDR cells (Valverde et al., 1992; Gill et al.,
1992), essentially marries the first two by suggesting that
MDR protein functions as both a drug pump and a C1-
channel or channel regulator (Hardy et al., 1995). It remains
to be unequivocally proven whether MDR protein is a CF-
channel, and in fact some recent data (Ehring et al., 1994)
appear to contradict previous work (Valverde et al., 1992),
while other recent data (Gill et al., 1992; Altenberg et al.,
1994) apparently support it. Luckie et al. (1994) have sug-
gested that anomalous ion conductance in MDR cells may
be the result of a higher "sensitivity" of endogenous chan-
nels to hypotonicity caused by some combination of drug
selection and MDR protein overexpression, and more re-
cently Hardy et al. (1995) have determined that some com-
plexity may be due to different levels of protein kinase C
activity in different cell types. In any case, interestingly,
overexpression of the MRP homologue has also been asso-
ciated with anomalous CF- conductance (Jirsch et al.,
1993).
It perhaps bears mentioning that many years of contro-
versy accompanied elucidation of CF- channel function for
the CFTR and controversy continues to this day with regard
to understanding regulation of the channel. If the MDR
protein does function as a channel it is unclear what gates its
conductance, and if it modulates some other endogenous
conductance, it is unclear what channels are being per-
turbed. To further complicate the picture, there is wide
variability in the cell types studied to date and most have
been selected with potent chemotherapeutic drugs that can
perturb cells in many ways. Bear (1994) has confirmed that
CF- conductance specific to MDR cells may be blocked by
some chemotherapeutic drugs; thus, using drug selected
cells in these experiments introduces complications. Also,
the hypotonic shock used to induce anomalous conductance
likely represents indirect "gating," and effects could be very
different in different cell types. Cell lines of B-cell lineage
used in Ehring et al. (1994) are unlikely to behave identi-
cally relative to fibroblasts used in other work. In any case,
if the MDR protein does indeed function as some type of
CF- transporter, and/or stimulates CF- channel activity, it
would be predicted to have important effects on plasma
membrane electrochemical potential. Thus, facets of the
third model support the second model.
We suggest that membrane depolarization plays a key
role in MDR, since decreased A'T has been measured for
true mu MDR 1 transfectants (Luz et al., 1994) and corre-
lated with resistance in a series of MDR cells (Roepe et al.,
1993), and appears to play some role in the CFTR-mediated
MDR phenotype. Also, model studies have clearly estab-
lished that diffusion and partitioning of the hydrophobic
cations vincristine and doxorubicin are highly dependent on
the magnitude ofAT (Bally et al., 1985; Mayer et al., 1985;
Praet et al., 1993). Since both the CFTR and MDR protein
may increase CF- conductance (Stutts et al., 1993; Bear et
al., 1992; Valverde et al., 1992; Gill et al., 1992; Hardy et
al., 1995), which is predicted to lower AT, CFTR and MDR
transfectants may share the property of drug resistance
through membrane depolarization. Since doxorubicin and
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vincristine are lipophilic cations, resistance to these is not
totally unexpected in the CFTR transfectants. Importantly,
A'T perturbations may indicate surface potential perturba-
tions that may have important effects. However, if resis-
tance in the CFTR clones is due to membrane depolariza-
tion, the observed colchicine resistance is provocative, since
this hydrophobic drug does not harbor positive charge (see
below).
The present data may be interpreted in the context of any
of the models, but we favor the second model, because of
the obvious specificity difficulties inherent in the first
model, kinetic evidence that argues against active efflux of
drugs in MDR cells and these CFFR transfectants (L. J.
Robinson and P. D. Roepe, submitted for publication), and
the scarcity of integral membrane proteins that function as
both pumps and channels as suggested by the third model.
However, based on previous hypotheses (Gill et al., 1992;
Hardy et al., 1995) one could speculate that CFTR is an-
other example of a channel or channel regulator that also
pumps chemotherapeutics. This hypothesis initially appears
unlikely because of the relative paucity of evidence for
copious ATP hydrolysis by the CFITR (in analogy to MDR
protein, energy for active drug transport would presumably
be required in the form of ATP hydrolysis), unless energy
for active transport is provided in the form of some ion
gradient (e.g., H+ or Cl-). Further detailed drug transport
measurements that examine the kinetic and thermodynamic
predictions of such a model will be helpful in this regard.
Alternatively, we suggest, via the second model, that the
exhibited colchicine resistance is due to an indirect effect of
membrane depolarization. Possibilities include 1) altered
vesicle traffic; 2) perturbation in tubulin organization near
the plasma membrane (i.e. altered availability of drug tar-
get; see Aszalos et al., 1986); 3) changes in membrane
fluidity or leaflet distribution of lipid. All of these have
previously been observed in MDR cells and could conceiv-
ably be perturbed by alterations in plasma membrane At.
Our results demonstrate a new property for the CFTR
(which can be added to the list already containing Cl-
channel, ion channel regulator, and water channel), namely,
that overexpression may lead to chemotherapeutic drug
resistance. Thus, a third member of the ABC transporter
family shares this important property. The additional shared
characteristics of anomalous Cl- conductance and mem-
brane depolarization in cells overexpressing the CFTR or
MDR protein suggest that the ability of these proteins to
influence passive drug translocation represents an important
mechanism of drug resistance that does not necessarily
require direct active drug transport. Finally, these data
should be considered with regard to evolving therapy of CF
(Collins, 1992), which may result in persistent overexpres-
sion of the CFTR.
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